Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial.
Vaginal atrophy is a common chronic condition among postmenopausal women that can affect their quality of life. Recent studies have evaluated new treatment alternatives for vaginal atrophy; however, few therapeutic options have been thoroughly evaluated. This study aimed to compare the effectiveness and adverse effects of estrogen, testosterone, polyacrylic acid, and placebo lubricant for the treatment of postmenopausal women with vaginal atrophy.



We conducted a randomized clinical trial with 80 postmenopausal women aged between 40 and 70 years who were being followed up at the Menopause Clinic of CAISM UNICAMP between November 2011 and January 2013. Women were randomly assigned to topical vaginal treatment with estrogen, testosterone, polyacrylic acid, and placebo lubricant, three times a week for 12 weeks. We used the vaginal maturation index, pH, vaginal health score, vaginal flora, laboratory tests, and ultrasound to evaluate changes of vaginal atrophy at baseline and after 6 and 12 weeks of treatment.



After a 12-week treatment with topical estrogen and testosterone compared with the lubricant, an increased percentage of participants had vaginal pH less than 5, increased vaginal score, and an increase in the number of lactobacilli. Treatment with topical estrogen improved the vaginal maturation index and showed increased levels of estradiol in three women. No changes were observed in the endometrial evaluation of all treatment groups.



After a 12-week treatment with testosterone and estrogen compared with placebo lubrication, there was a significant improvement in vaginal trophism in postmenopausal women with vaginal atrophy.
Department of Obstetrics and Gynecology, State University of Campinas, São Paulo, Brazil.
Tatiane
T
Fernandes
Lucia Helena
LH
Costa-Paiva
Adriana Orcesi
AO
Pedro
Luiz Francisco Cintra
LF
Baccaro
Aarão Mendes
AM
Pinto-Neto
D000180:Acrylic Resins / Q000008:administration & dosage*; D000282:Administration, Intravaginal; D000328:Adult; D000368:Aged; D001284:Atrophy / Q000188:drug therapy; D004967:Estrogens / Q000008:administration & dosage*; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D057194:Intention to Treat Analysis; D008875:Middle Aged; D017698:Postmenopause; D016037:Single-Blind Method; D043343:Testosterone Propionate / Q000008:administration & dosage*; D016896:Treatment Outcome; D014621:Vagina / Q000187:drug effects / Q000473:pathology*; D014622:Vaginal Creams, Foams, and Jellies / Q000008:administration & dosage; D014623:Vaginal Diseases / Q000188:drug therapy* / Q000473:pathology
D000180:Acrylic Resins; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D014622:Vaginal Creams, Foams, and Jellies; C006903:carbopol 940; D043343:Testosterone Propionate